Compare Crispr Therapeutics AG (CRSP) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while YieldMax Universe Fund of Option Income ETFs trades at $7.84. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| CRSP | YMAX | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $14.00 |
52-Week Low | $44.34 | $7.51 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
YMAX trades at $7.82, down 1.26% today amid bearish technical signals with 16 sell indicators versus 1 buy. The ETF maintains weekly dividend distributions but faces scrutiny over its fund-of-funds structure and 1.33% fee. Recent articles highlight shrinking payouts and cost concerns, while technical analysis shows all moving averages signaling bearish momentum with neutral oscillators.
The outlook remains cautious as high fees and declining distributions pressure investor returns. Key risks include structural costs eroding yields and bearish technical momentum. Investment opportunity hinges on volatility-driven income generation, but current sentiment suggests limited upside without improved cost efficiency or market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
